Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 11/20 | 0.47 |
| ▸ | CNR1 | P21554 | 6/20 | 0.47 |
| ▸ | CETP | P11597 | 4/20 | 0.40 |
| ▸ | GPR55 | Q9Y2T6 | 2/20 | 0.39 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.38 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.38 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | ATM | Q13315 | 1/20 | 0.36 |
| ▸ | IAPP | P10997 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5587103 | 0.95 | CNR2 (0.42) | CNR2CNR1CETPGPR55SLC6A2 | |
| SCHEMBL5587327 | 0.89 | SLC6A2 (0.37) | CNR2CNR1CETPGPR55SLC6A2 | |
| SCHEMBL28187956 | 0.89 | CNR2 (0.50) | CNR2CNR1CETPGPR55SLC6A2 | |
| SCHEMBL5586872 | 0.83 | SLC6A2 (0.42) | SLC6A2SLC6A3SLC6A4ALDH1A1 | |
| SCHEMBL10780105 | 0.80 | CNR1 (0.49) | CNR2CNR1CETPMEN1ALDH1A1 | |
| SCHEMBL28227454 | 0.78 | SLC6A3 (0.40) | CNR2CNR1CETPGPR55SLC6A2 | |
| SCHEMBL8743740 | 0.77 | LIPG (0.44) | CNR2CNR1CETPGPR55SLC6A2 | |
| SCHEMBL5587262 | 0.76 | SLC6A4 (0.37) | CNR2CNR1CETPSLC6A2SLC6A3 | |
| SCHEMBL9355996 | 0.76 | HDAC4 (0.47) | CNR2CNR1CETPGPR55SLC6A2 | |
| SCHEMBL5678354 | 0.76 | CETP (0.41) | CNR2CNR1CETPGPR55SLC6A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7247687-B2 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2007-07-24 | — | — | US | disclosed |
| EP-1521758-B1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEM PATENTS INC (US) | 2006-05-24 | — | — | EP | disclosed |
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | EXXONMOBIL CHEMICAL PATENTS INC. | 2006-03-02 | — | — | US | disclosed |
| EP-1521758-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | Exxonmobil Chemical Patents Inc. (US) | 2005-04-13 | — | — | EP | disclosed |
| WO-2004007509-A1 | LATE TRANSITION METAL CATALYSTS FOR OLEFIN POLYMERIZATION AND OLIGOMERIZATION | EXXONMOBIL CHEMICAL PATENTS INC. (US) | 2004-01-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060047094-A1 | Late transition metal catalysts for olefin polymerization and oligomerization | MLX, LOX, LMTK3 | CNR2 3732/4885CNR1 3323/4885CETP 2745/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.